Diagnosed with COVID-19; Lichen planus; Shingrix completed in 10/2020, shingles in 9/2021/suspected vaccination failure; Shingles 4 times; This case was reported by a physician via other manufacturer and described the occurrence of vaccination failure in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis, TOZINAMERAN (COVID-19 PFIZER/BIONTECH VACCINE) for prophylaxis and TOZINAMERAN (COVID-19 PFIZER/BIONTECH VACCINE) for prophylaxis.   The patient's past medical history included glaucoma. Previously administered products included steroid cream (steroid cream prior to vaccination). Concurrent medical conditions included drug allergy (Sulfa, Penicillin, Doxycycline, Avelox).   On 23rd October 2020, the patient received the 2nd dose of Shingrix. On an unknown date, the patient received the 1st dose of Shingrix. On 29th January 2021 12:00, the patient received the 2nd dose of COVID-19 PFIZER/BIONTECH VACCINE (intramuscular). On 1st January 2021 12:00, the patient received the 1st dose of COVID-19 PFIZER/BIONTECH VACCINE (intramuscular). In September 2021, between 10 and 12 months after receiving Shingrix and unknown after receiving Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. In May 2022, the patient experienced lichen planus. On an unknown date, the patient experienced covid-19. The patient was treated with valaciclovir hydrochloride (Valtrex) and steroids nos (Steroid (Not Specified)). On an unknown date, the outcome of the vaccination failure, lichen planus and covid-19 were unknown and the outcome of the shingles was not recovered/not resolved.   It was unknown if the reporter considered the vaccination failure, shingles, lichen planus and covid-19 to be related to Shingrix. It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix.     Linked case(s) involving the same patient:  US2023AMR032694, US2023AMR032695, US2023AMR032698   Additional Information: GSK Receipt Date: 27-FEB-2023 Reporter's comment: The batch/lot was Unknown, and not available or provided to reporter at the time of report completion facility where the most recent COVID-19 vaccine was administered at Pharmacy or Drug Store. No List of any other medications the patient received within 2 weeks of vaccination. The patient experienced Shingles in the same body region four times with normal immune system on September 2021, December 2021, May 2022, and December 2022. Shingrix completed on 123rd Octover 2020. Also developed lichen planus on May 2022. The treatment received were Valtrex, steroid injections, steroid cream Prior to vaccination. The patient was diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The Pfizer have permission to contact the reporter about this event. Additional supportive information: This case was considered as suspected vaccination failure as details regarding laboratory confirmation regarding shingles were unknown at the time of reporting. Sender's Comments:  US-GSK-US2023AMR032694:Same reporter US-GSK-US2023AMR032695:Same reporter US-GSK-US2023AMR032698:Same reporter